Alcon Announces Global Removal of CyPass Micro-Stent for Surgical Glaucoma

 Alcon Announces Global Removal of CyPass Micro-Stent for Surgical Glaucoma

Alcon Announces Global Removal of CyPass Micro-Stent for Surgical Glaucoma

Shots:
  •  Alcon is removing CyPass globally revealing its unmet needs with safety of patients with the guidance for surgeons to stop its further use and return the fresh devices
  •  The above decision is on the basis of five-year data from COMPASS-XT long-term safety study
  • The study showed reduction in intraocular pressure at two yrs, resulting a little difference in endothelial cell loss and at five yrs experienced reduction in endothelial cell loss vs cataract surgery alone
Click here to read full press release/ article | Ref: Novartis | Image:  Novartis

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post